Oncolytics Biotech Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Oncolytics Biotech Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 93% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-330.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 93% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-104.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 83% of Healthcare companies in United States.
Cash Cushion Ratio
+7%Cash, after subtracting all debt, equals 7% of its market value (net cash).
Lower than 54% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (8)
Oncolytics Biotech Inc. made a loss over the last year. Oncolytics Biotech Inc. owes $1.80 for every $1 it owns. Oncolytics Biotech Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossOncolytics Biotech Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-10.64Oncolytics Biotech Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$66 MThe total market value of all of Oncolytics Biotech Inc.'s shares at today's price (share price × number of shares), smaller than 71% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeOncolytics Biotech Inc.'s net worth is negative ($6 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.80×Oncolytics Biotech Inc. owes $1.80 for every $1 it owns, so it owes more than it owns, higher than 96% of Healthcare companies in United States.
Dividend yield
NoneOncolytics Biotech Inc. does not currently pay a dividend.
Profit growth
LossOncolytics Biotech Inc. made a loss in each of the last two years.
Cash vs debt
Net cashOncolytics Biotech Inc. held $5 M more cash than debt (net cash) at Dec 2025.
Questions
How much does Oncolytics Biotech Inc. owe compared with what it owns?
Oncolytics Biotech Inc. owes $1.80 for every $1 it owns, so it owes more than it owns, higher than 96% of Healthcare companies in United States.
Does Oncolytics Biotech Inc. pay a dividend?
No. Oncolytics Biotech Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.